Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in:

02.09.2024 | Colorectal Cancer

Watch and Wait is Changing: We Need to Change How We Count Costs

verfasst von: Christopher Rao, FRCS(Gen), PhD, Arthur Sun Myint, FRCR

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Auszug

Murshed et al. should be congratulated on their systematic review of the published literature on the economic analysis of watch and wait. This represents a well-conducted systematic review that captures most of the relevant literature. The authors have performed comprehensive evaluation of the methodological quality of the included studies and their attempts to draw common themes from this heterogeneous body of literature is laudable.1 …
Literatur
1.
2.
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7.CrossRefPubMedPubMedCentral
3.
Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83.CrossRefPubMed
4.
Drummond M, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th edn. Oxford: Oxford University Press; 2015.
5.
Gerard JP, Barbet N, Benezery K. Organ preservation for T2–T3 rectal cancer: opportunistic or planned strategy. Oncotarget. 2019;10(37):3431–2.CrossRefPubMedPubMedCentral
6.
Rao C, Sun Myint A, Athanasiou T, et al. Avoiding radical surgery in elderly patients with rectal cancer is cost-effective. Dis Colon Rectum. 2017;60(1):30–42.CrossRefPubMed
7.
Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.CrossRef
8.
Wurschi GW, Ruhle A, Domschikowski J, et al. Patient-relevant costs for organ preservation versus radical resection in locally advanced rectal cancer. Cancers (Basel). 2024;16(7).
9.
Rao C, Smith FM, Martin AP, et al. A cost-effectiveness analysis of contact X-ray brachytherapy for the treatment of patients with rectal cancer following a partial response to chemoradiotherapy. Clin Oncol (R Coll Radiol). 2018;30(3):166–77.CrossRefPubMed
10.
Habr-Gama A, Sao Juliao GP, Vailati BB, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269(1):102–7.CrossRefPubMed
11.
Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.CrossRefPubMed
12.
Sun Myint A, Smith FM, Gollins SW, et al. Dose escalation using contact x-ray brachytherapy (Papillon) for rectal cancer. Does it improve the chance of organ preservation? Br J Radiol. 2017:20170175.
13.
Gerard JP, Barbet N, Schiappa R, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356–67.CrossRefPubMed
14.
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56.CrossRefPubMedPubMedCentral
15.
Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465–74.CrossRefPubMed
16.
Stijns RCH, de Graaf EJR, Punt CJA, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: The CARTS study. JAMA Surg. 2019;154(1):47–54.CrossRefPubMed
17.
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76.CrossRefPubMedPubMedCentral
18.
Sun Myint A, Than N, Pacé-Loscos T, et al. Radiation dose esclation with contact X-ray brachytherapy (Papillon) and quality of life in patients with rectal cancer: results from the phase 3 randomised trial OPERA. 2024.
19.
Bach SP, Gilbert A, Brock K, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2021;6(2):92–105.CrossRefPubMed
20.
Bennett H, Rao C, Batten L, et al. Low energy contact X-ray brachytherapy for treatment of rectal cancer: a health technology appraisal by Health Technology Wales. Colorectal Dis. 2024;26(5):1053–8.CrossRefPubMed
21.
Bach SP, STAR-TREC Collaborative. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches. Colorectal Dis. 2022;24(5):639-651.
22.
Crean R, Glyn T, McCombie A, Frizelle F. Comparing outcomes and cost in surgery versus watch & wait surveillance of patients with rectal cancer post neoadjuvant long course chemoradiotherapy. ANZ J Surg. 2024;94(6):1151–60.CrossRefPubMed
23.
Hupkens BJP, Martens MH, Stoot JH, et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection: a matched-controlled study. Dis Colon Rectum. 2017;60(10):1032–40.CrossRefPubMed
24.
Kaul S, Rao C, Mane R, et al. Is the management of rectal cancer using a watch and wait approach feasible, safe and effective in a publicly funded general hospital? Clin Oncol (R Coll Radiol). 2022;34(1):e25–34.CrossRefPubMed
25.
Bibi S, Edilbe MW, Rao C. The cost-effectiveness of watch and wait for rectal cancer. Clin Oncol (R Coll Radiol). 2023;35(2):132–7.CrossRefPubMed
26.
Fernandez LM, Sao Juliao GP, Renehan AG, et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the international watch and wait database. Dis Colon Rectum. 2023;66(1):41–9.CrossRefPubMed
27.
Socha J, Kepka L, Michalski W, Paciorek K, Bujko K. The risk of distant metastases in rectal cancer managed by a watch-and-wait strategy: A systematic review and meta-analysis. Radiother Oncol. 2020;144:1–6.CrossRefPubMed
28.
Bhimani N, Wong GYM, Molloy C, et al. Cost of treating metastatic colorectal cancer: a systematic review. Public Health. 2022;211:97–104.CrossRefPubMed
29.
Bakkerus L, Buffart LM, Buffart TE, et al. Health-related quality of life in patients with metastatic colorectal cancer undergoing systemic therapy with or without maximal tumor debulking. J Natl Compr Canc Netw. 2023;21(10):1059–66.CrossRefPubMed
30.
Lehtomaki K, Stedt HP, Osterlund E, et al. Health-related quality of life in metastatic colorectal cancer patients treated with curative resection and/or local ablative therapy or systemic therapy in the Finnish RAXO-study. Cancers (Basel). 2022;14(7).
Metadaten
Titel
Watch and Wait is Changing: We Need to Change How We Count Costs
verfasst von
Christopher Rao, FRCS(Gen), PhD
Arthur Sun Myint, FRCR
Publikationsdatum
02.09.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-16175-y

Weitere Artikel der Ausgabe 12/2024

ASO Visual Abstract: Incidence of High-Risk and Malignant Pathological Findings in Transgender and Gender-Diverse Individuals Undergoing Gender-Affirming Mastectomy

  • ASO Visual Abstract

ASO Visual Abstract: Contrast-Enhanced Mammography in Local Staging of Screen-Detected Breast Cancer

  • ASO Visual Abstract

Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study

  • Open Access
  • Thoracic Oncology

Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma

  • Open Access
  • Pancreatic Tumors

ASO Visual Abstract: PROMRIINE (PRe-operatory Magnetic Resonance Imaging is INEffective) Study: A Systematic Review and Meta-analysis of the Impact of Magnetic Resonance Imaging on Surgical Decisions and Clinical Outcomes in Women with Breast Cancer

  • ASO Visual Abstract

ASO Visual Abstract: Comparison of the Oncological Outcomes of Patients with Mid-to-Lower Esophageal Squamous Cell Carcinoma and Undergoing Surgical Treatment Using the Ivor–Lewis or McKeown Operation

  • ASO Visual Abstract

Neu im Fachgebiet Chirurgie

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Op.-Entscheidung bei Divertikulitis: Lebensqualität zählt!

Soll man Menschen, die schon mehrfach schmerzhafte Divertikulitisepisoden durchgemacht haben, eine Op. anbieten? Ein Team aus Helsinki rät, dies von der Lebensqualität abhängig zu machen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise